<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Int Rep</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Int Rep</journal-id><journal-title-group><journal-title>Kidney International Reports</journal-title></journal-title-group><issn pub-type="epub">2468-0249</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29142979</article-id><article-id pub-id-type="pmc">5678834</article-id><article-id pub-id-type="publisher-id">S2468-0249(17)30021-9</article-id><article-id pub-id-type="doi">10.1016/j.ekir.2017.02.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ramachandran</surname><given-names>Raja</given-names></name><email>drraja_1980@yahoo.co.in</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Ashok Kumar</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Vinod</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Siva Tez Pinnamaneni</surname><given-names>Venkata</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Nada</surname><given-names>Ritambhra</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Ratan</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Vivek</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rathi</surname><given-names>Manish</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kohli</surname><given-names>Harbir Singh</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Krishan Lal</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Sakhuja</surname><given-names>Vinay</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Jha</surname><given-names>Vivekanand</given-names></name><email>vjha60@gmail.com</email><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India</aff><aff id="aff2"><label>2</label>Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India</aff><aff id="aff3"><label>3</label>Department of Nephrology, Oxford University, Oxford, UK</aff><aff id="aff4"><label>4</label>The George Institute for Global Health, New Delhi, India</aff><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Correspondence:</bold> Raja Ramachandran, Department of Nephrology, PGIMER, Chandigarh-160012, India.Department of NephrologyPGIMERChandigarh-160012India <email>drraja_1980@yahoo.co.in</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Vivekanand Jha, The George Institute for Global Health, 311-312, Third Floor, Elegance Tower, Plot No. 8, Jasola District Centre, New Delhi 110025, India.The George Institute for Global Health311-312, Third Floor, Elegance Tower, Plot No. 8, Jasola District CentreNew Delhi 110025India <email>vjha60@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>2</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2017</year></pub-date><volume>2</volume><issue>4</issue><fpage>610</fpage><lpage>616</lpage><history><date date-type="received"><day>7</day><month>12</month><year>2016</year></date><date date-type="rev-recd"><day>3</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 International Society of Nephrology. Published by Elsevier Inc.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>International Society of Nephrology</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Introduction</title><p>Both cCTX/GCs and CNIs are recommended as first-line agents in the management of PMN. The present study is an extended report of patients randomized to receive TAC/GCs or cCTX/GCs at 2 years post randomization.</p></sec><sec><title>Methods</title><p>Seventy patients enrolled in the clinical trial Tacrolimus Combined With Corticosteroids Versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial were followed quarterly between 12 and 24 months. At the end of 24 months, 3 patients were lost to follow-up.</p></sec><sec><title>Results</title><p>At 18 months, 66% and 89% (<italic>P</italic>&#x000a0;= 0.04) were in remission in TAC/GCs and cCTX/GCs groups, respectively. At 18 and 24 months, 60% and 86% (<italic>P</italic>&#x000a0;= 0.03) of cases were in remission in the TAC/GCs and cCTX/GCs groups, respectively. At 18 months, 57% and 83% (<italic>P</italic>&#x000a0;= 0.03) of the patients in TAC/GCs and cCTX/GCs groups were in remission without need of any additional immunosuppression (persistent remission) and, at 24 months, 43% and 80% (<italic>P</italic>&#x000a0;= 0.002) were in persistent remission in TAC/GCs and cCTX/GCs groups, respectively. Relapse rate after any remission was 40% and 6.7% in TAC/GCs and cCTX/GCs groups, respectively (<italic>P</italic>&#x000a0;= 0.007). There was an association of aPLA2R titers with remission or resistance (<italic>P</italic>&#x000a0;= 0.006) in relapsing PMN. The significant decrease in eGFR after 12 months of TAC/GCs therapy normalized at 18 and 24 months.</p></sec><sec><title>Discussion</title><p>At 2 years after randomization, relapse rates are higher for TAC/GCs compared with cCTX/GCs in PMN patients. Thus, cCTX/GCs are better than TAC/GCs in the longer term in PMN patients.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>cyclophosphamide</kwd><kwd>membranous nephropathy</kwd><kwd>PLA2R</kwd><kwd>randomized control trial</kwd><kwd>steroids</kwd><kwd>tacrolimus</kwd></kwd-group></article-meta></front><body><p>Both calcineurin inhibitors (CNIs) and cyclical cyclophosphamide (cCTX) with glucocorticoids (GCs) (CTX/GCs) are recommended in the management of primary membranous nephropathy (PMN).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> The 2 regimes are equally efficacious, but have different adverse event profiles.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref></p><p>We reported a remission rate at the end of 1 year of 77% and 71% with cCTX/GCs and tacrolimus (TAC) with steroids, respectively.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> At least 3 other randomized controlled trials have reported the 12-month remission rates of 65% to 89% and 44% to 69%,<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref> with TAC/GCs and cCTX/GCs, respectively.</p><p>Cattran <italic>et&#x000a0;al.</italic><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> reported a remission rate of 75% after 6-month treatment with cyclosporine and steroids. The remission rates fell to 46% and 39% at 12 and 24&#x000a0;months once cyclosporine was stopped. In other studies, the relapse rates after stopping TAC/cyclosporine and cCTX/GCs range from 47% to 50% and 20% to 31%, respectively.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref> The high rates of relapse compounded with nephrotoxicity of long-term use of CNIs, makes it worthwhile to study the remission rates after stopping the drug. The present study reports the remission rates at 18 and 24 months.</p><sec id="sec1"><title>Methods</title><p>The present report is an extended (2-year) follow-up of patients enrolled in a randomized controlled trial that compared tacrolimus combined with corticosteroids and cCTX/GCs (Tacrolimus Combined With Corticosteroids Versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial; CTRI/2013/10/004061) carried at the Department of Nephrology, PGIMER, Chandigarh, India.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Briefly, the study included adults with biopsy-proven PMN and persistent nephrotic syndrome in spite of 6 months of nonimmunosuppressive symptomatic treatment with full angiotensin-blockade.</p><sec id="sec1.1"><title>Therapy</title><p>Patients received either oral prednisolone (0.5 mg/kg/d for&#x000a0;6 months and subsequent taper by 0.1 mg/kg/wk) and <italic>TAC</italic> (trough level&#x000a0;= 7.46 &#x000b1; 1.28 ng/ml for the first 6 months and 4.83 &#x000b1; 0.59 ng/ml for next 6 months)<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> for 12 months, followed by taper by 50% every 2 weeks to stop or cCTX/GCs (6-month course of alternate months of steroid and cyclophosphamide).<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib11" ref-type="bibr">11</xref></p></sec><sec id="sec1.2"><title>Endpoint</title><p>A total of 70 patients were enrolled in the study starting from September 21, 2011 to December 2, 2013. Two-year follow-up was completed by December 2015. The primary endpoint of the trial was remission rate at the end of 6 and 12 months.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> At the end of 12 months, 71% (<italic>n</italic>&#x000a0;= 25) and 77% (<italic>n</italic>&#x000a0;= 27) of the study participants achieved remission.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> During the study it was decided to continue the follow-up of the enrolled patients without any prespecified interventions. Patients were followed quarterly from months 12 to 24 with proteinuria, serum creatinine, and albumin. The Institute Ethics Committee approved the study, and all subjects provided written informed consent.</p></sec><sec id="sec1.3"><title>Definitions</title><p>Nephrotic syndrome: proteinuria of &#x0003e;4 g/d or&#x000a0;&#x02265;2.0 g/d along with serum albumin&#x000a0;&#x0003c;2.5 g/dl.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib11" ref-type="bibr">11</xref> Complete remission: proteinuria &#x0003c;500 mg/d with normal serum albumin (&#x02265;3.5 g/dl) and serum creatinine. Partial remission: proteinuria&#x000a0;&#x02265;500 mg/d, but &#x0003c;2 g/d or&#x000a0;&#x0003c;50% of baseline with normal serum albumin (&#x02265;3.5 g/dl) and serum creatinine. Relapse: nephrotic range proteinuria after any remission (complete remission or partial remission).</p></sec><sec id="sec1.4"><title>Statistical Analysis</title><p>As described elsewhere,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> the study was designed as a noninferiority trial (10%), with a sample size of 70, equally divided to receive either TAC/GCs or cCTX/GCs.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> The analysis was based on intention to treat. Intention to treat was performed with last value carried forward. In addition, we have also analyzed the number of patients who persisted to have remission without need of any secondary immunosuppression. Continuous data are reported as mean &#x000b1; SD. Categorical values are represented as absolute values and percentages. The primary analysis was done using a &#x003c7;2 or Fisher exact test. For secondary outcomes both <italic>t</italic> test and &#x003c7;2 test were used to compare the difference between the 2 groups. Mann-Whitney <italic>U</italic> test was used to compare nonparametric data. For association of antibodies to M-type phospholipase A2 receptor (aPLA2R) to relapse, a simple visual impression was performed, for treatment outcome with secondary immunosuppression a &#x003c7;2 or Fisher exact test was performed (comparing clinical remission or resistance with aPLA2R presence or absence) and analysis of variance for estimated glomerular filtration rate (eGFR) comparison. Statistical analyses were done using Graph Pad Prism 6 (San Diego, CA). <italic>P</italic>&#x000a0;&#x0003c; 0.05 was considered significant and was 2-sided.</p></sec></sec><sec id="sec2"><title>Results</title><p>A total of 84 cases were screened, of which 70 were enrolled in the study (35 randomized to receive either cCTX/GCs or TAC/GCs). Sixty-seven cases completed 24 months of follow-up. There were no differences in the baseline parameters between the study groups.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p><p>The outcome at the end of 6 and 12 months is mentioned elsewhere.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> At the end of 18 and 24 months, 23 (65.7%) versus 31 (88.6%) (difference of 22.86%; 95% confidence interval [CI]: 3.30&#x02013;44.7; <italic>P</italic>&#x000a0;= 0.04) cases and 21 (60%) versus 30 (85.7%) (difference of 25.71%; 95%CI 5.81, 48.64; <italic>P</italic>= 0.03) patients were in remission in TAC/GCs and cCTX/GCs groups, respectively. The number of patients in complete and partial remission at 18 and 24 months after starting therapy is shown in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Remission rate at various time points (1&#x02014;intention to treat; 2&#x02014;remission without any secondary immunosuppression). cCTX, cyclical cyclophosphamide; GCs, glucocorticoids; TAC, tacrolimus.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Clinical outcome at various time points</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">18 mo<hr/></th><th colspan="2">24 mo<hr/></th></tr><tr><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th></tr></thead><tbody><tr><td>Remission (ITT)<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="char">23 (65.7)<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td align="char">31 (88.6)<xref rid="tbl1fnb" ref-type="table-fn">c</xref></td><td align="char">21 (60)<xref rid="tbl1fnd" ref-type="table-fn">d</xref></td><td align="char">30 (85.7)<xref rid="tbl1fnd" ref-type="table-fn">e</xref></td></tr><tr><td>CR</td><td align="char">15 (42.8)</td><td align="char">20 (57.2)</td><td align="char">12 (34.3)</td><td align="char">20 (57.2)</td></tr><tr><td>PR</td><td align="char">08 (22.8)</td><td align="char">11 (31.4)</td><td align="char">09 (25.7)</td><td align="char">10 (28.5)</td></tr><tr><td>Resistant</td><td align="char">07 (20.0)</td><td align="char">04 (11.4)</td><td align="char">07 (20.0)</td><td align="char">03 (8.6)</td></tr><tr><td>Relapse</td><td align="char">05 (14.3)<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td>NA<xref rid="tbl1fnf" ref-type="table-fn">g</xref></td><td align="char">07 (20.0)<xref rid="tbl1fnf" ref-type="table-fn">h</xref></td><td align="char">02 (5.7)<xref rid="tbl1fnf" ref-type="table-fn">i</xref></td></tr><tr><td>Remission<xref rid="tbl1fnj" ref-type="table-fn">j</xref></td><td align="char">20 (57.1)<xref rid="tbl1fnk" ref-type="table-fn">k</xref></td><td align="char">29 (82.8)<xref rid="tbl1fnk" ref-type="table-fn">l</xref></td><td align="char">15 (42.8)<xref rid="tbl1fnm" ref-type="table-fn">m</xref></td><td align="char">28 (80)<xref rid="tbl1fnm" ref-type="table-fn">n</xref></td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Values are n (%).</p></fn><fn id="tspara0020"><p>cCTX, cyclical cyclophosphamide; CI, confidence interval; CR, proteinuria &#x0003c;500 mg/d with normal serum albumin (&#x02265;3.5 g/dl) and serum creatinine; GCs, glucocorticoids; ITT, intention to treat; NA not applicable; PR, proteinuria &#x02265;500&#x000a0;mg/d, but&#x000a0;&#x0003c;2 g/d or&#x000a0;&#x0003c;50% of baseline with normal serum albumin (&#x02265;3.5 g/dl) and serum creatinine; TAC, tacrolimus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Included all remission irrespective of the use of second line agents, TAC/GCs, and cCTX/GCs.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b&#x02217;c</label><p id="ntpara0015">0.24 (95% CI: 0.07&#x02013;0.86; <italic>P</italic>&#x000a0;= 0.04).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnd"><label>d&#x02217;e</label><p id="ntpara0020">0.25 (95% CI: 0.07&#x02013;0.80; <italic>P</italic>&#x000a0;= 0.03).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnf"><label>f+h versus g+i</label><p id="ntpara0025"><italic>P</italic>&#x000a0;= 0.007.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnj"><label>j</label><p id="ntpara0030">Cases with remission without any need of any further immunosuppression.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnk"><label>k&#x02217;l</label><p id="ntpara0035">0.27 (95% CI: 0.08&#x02013;0.87; <italic>P</italic>&#x000a0;= 0.03).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnm"><label>m&#x02217;n</label><p id="ntpara0040">0.18 (95% CI: 0.06&#x02013;0.54; <italic>P</italic>&#x000a0;= 0.002).</p></fn></table-wrap-foot></table-wrap></p><p>Twenty subjects (57.1%) and 29 (82.8%) maintained clinical remission without need of any further immunosuppressive agents in the TAC/GCs and cCTX/GCs groups, respectively, at 18 months (difference of 25.71%; 95% CI: 5.46&#x02013;49.24; <italic>P</italic>&#x000a0;= 0.03), and 15 (42.8%) and 28 (80%) maintained remission at 24 months in TAC/GCs and cCTX/GCs groups, respectively (difference of 37.14; 95% CI: 17.68&#x02013;61.96; <italic>P</italic>&#x000a0;= 0.002) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). There was no difference in proteinuria between groups at different follow-up points (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). However, serum albumin was significantly lower in the TAC/GCs compared with the cCTX/GCs group at 15 (<italic>P</italic>&#x000a0;= 0.02), 18 (<italic>P</italic>&#x000a0;= 0.01), 21 (<italic>P</italic>&#x000a0;= 0.005), and 24 months (<italic>P</italic>&#x000a0;= 0.02) (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). There was no difference in serum creatinine and eGFR between both the groups at various above-mentioned time points. The details of the proteinuria, serum albumin, and serum creatinine are mentioned in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>. Among cases achieving any remission, 10 subjects (40%) and 2 (6.7%) had relapsed at 24 months in TAC/GCs and cCTX/GCs (3 subjects had remission after 12 months of starting cCTX/GCs, of which 1 relapsed) groups, respectively (<italic>P</italic>&#x000a0;= 0.0069).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Graphical representation of proteinuria (right) and serum albumin (left) at various time intervals. The values are expressed as means and SDs (vertical lines). BL, baseline; cCTX, cyclical cyclophosphamide; GCs, glucocorticoids; TAC, tacrolimus.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Outcome parameters at various time points</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">15 mo<hr/></th><th colspan="3">18 mo<hr/></th><th colspan="3">21 mo<hr/></th><th colspan="3">24 mo<hr/></th></tr><tr><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th><italic>P</italic> value</th><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th><italic>P</italic> value</th><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th><italic>P</italic> value</th><th>TAC/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th>cCTX/GCs<break/>(<italic>n</italic>&#x000a0;= 35)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Proteinuria (g/d)</td><td>2.23 &#x000b1; 3.59 (1.00&#x02013;3.47)</td><td>1.10 &#x000b1; 1.18 (0.70&#x02013;1.51)</td><td align="char">0.08</td><td>2.00 &#x000b1; 3.50 (0.80&#x02013;3.20)</td><td>1.00 &#x000b1; 1.12 (0.61&#x02013;1.38)</td><td align="char">0.11</td><td>2.30 &#x000b1; 3.53 (1.08&#x02013;3.51)</td><td>1.04 &#x000b1; 1.44 (0.54&#x02013;1.54)</td><td align="char">0.05</td><td>2.40 &#x000b1; 3.51 (1.19&#x02013;3.61)</td><td>1.27 &#x000b1; 1.67 (0.69&#x02013;1.84)</td><td align="char">0.08</td></tr><tr><td>Serum albumin (g/dl)</td><td>3.48 &#x000b1; 0.97 (3.15&#x02013;3.81)</td><td>3.93 &#x000b1; 0.54 (3.74&#x02013;4.12)</td><td align="char">0.02</td><td>3.51 &#x000b1; 0.90 (3.20&#x02013;3.82)</td><td>3.97 &#x000b1; 0.62 (3.76&#x02013;4.19)</td><td align="char">0.01</td><td>3.48 &#x000b1; 0.84 (3.18&#x02013;3.77)</td><td>3.97 &#x000b1; 0.56 (3.78&#x02013;4.17)</td><td align="char">0.005</td><td>3.57 &#x000b1; 0.89 (3.27&#x02013;3.88)</td><td>4.00 &#x000b1; 0.62 (3.79&#x02013;4.22)</td><td align="char">0.02</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>0.96 &#x000b1; 0.18 (0.89&#x02013;1.02)</td><td>0.93 &#x000b1; 0.26 (0.84&#x02013;1.02)</td><td align="char">0.62</td><td>0.95 &#x000b1; 0.17 (0.89&#x02013;1.01)</td><td>0.94 &#x000b1; 0.23 (0.86&#x02013;1.02)</td><td align="char">0.78</td><td>0.91 &#x000b1; 0.20 (0.84&#x02013;0.98)</td><td>0.93 &#x000b1; 0.21 (0.86&#x02013;1.00)</td><td align="char">0.64</td><td>0.98 &#x000b1; 0.25 (0.90&#x02013;1.07)</td><td>0.92 &#x000b1; 0.18 (0.86&#x02013;0.98)</td><td align="char">0.24</td></tr></tbody></table><table-wrap-foot><fn id="tspara0035"><p>Values are means &#x000b1; SDs and 95% confidence intervals.</p></fn><fn id="tspara0040"><p>cCTX, cyclical cyclophosphamide; GCs, glucocorticoids; TAC, tacrolimus.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec2.1"><title>Second Line Agents</title><p>Thirteen cases in the TAC/GCs group and 4 cases in the cCTX/GCs group received immunosuppressive treatment for relapsing or resistant disease. Nine cases of the TAC/GCs group received cCTX/GCs (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). At the end of 6 months of cCTX/GCs therapy, clinical and serological remission was achieved in 7 subjects (77.8%). The therapy was well tolerated, but for 2 cases, who developed upper respiratory tract infection. Three cases on cCTX/GCs received TAC therapy. Of the&#x000a0;3 cases, 1 patient (33.3%) achieved clinical remission at 12 months; however, the proteinuria relapsed on tapering TAC. Five cases (4 on TAC/GCs and 1 on cCTX/GCs) received a single dose of rituximab (375&#x000a0;mg/m<sup>2</sup>) with monthly monitoring of CD-19 (target&#x000a0;&#x0003c;1% CD-19 cells with absolute count of&#x000a0;&#x0003c;5&#x000a0;cells/&#x003bc;l). Rituximab was repeated on increase in CD-19 count (CD-19 &#x0003e;1% or&#x000a0;&#x02265;CD cells/&#x003bc;l). Remission was achieved in 3 cases (60%). The details are mentioned in <xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>. Among 17 subjects requiring a second course of immunosuppression, 16 (94.1%) were related to&#x000a0;aPLA<sub>2</sub>R. There was a significant association of aPLA<sub>2</sub>R to treatment outcome at the end of therapy (<italic>P</italic>&#x000a0;= 0.007).<table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Antibodies to PLA2R in patients with relapse</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case <italic>no</italic>.</th><th>Age /sex</th><th>Primary therapy</th><th>aPLA2R (RU/ml)<break/>(baseline)</th><th>aPLA2R (RU/ml)<break/>(6 mo)</th><th>aPLA2R (RU/ml)<break/>(12 mo)</th><th>aPLA2R (RU/ml)<break/>(relapse)</th></tr></thead><tbody><tr><td>1</td><td>48/F</td><td>TAC/GCs</td><td align="char">337.16</td><td align="char">3.32</td><td align="char">4.51</td><td align="char">221.71</td></tr><tr><td>2</td><td>60/F</td><td>TAC/GCs</td><td align="char">214.13</td><td align="char">1.25</td><td align="char">1.41</td><td align="char">322.37</td></tr><tr><td>3</td><td>41/M</td><td>TAC/GCs</td><td align="char">203.46</td><td align="char">4.24</td><td align="char">4.28</td><td align="char">186.67</td></tr><tr><td>4</td><td>42/M</td><td>TAC/GCs</td><td align="char">159.50</td><td align="char">1.30</td><td align="char">1.25</td><td align="char">294.73</td></tr><tr><td>5</td><td>40/M</td><td>TAC/GCs</td><td align="char">117.47</td><td align="char">6.26</td><td align="char">0.45</td><td>NA</td></tr><tr><td>6</td><td>38/M</td><td>TAC/GCs</td><td align="char">89.15</td><td align="char">2.06</td><td align="char">0.45</td><td align="char">56.68</td></tr><tr><td>7</td><td>36/M</td><td>TAC/GCs</td><td align="char">84.22</td><td align="char">15.04</td><td align="char">6.20</td><td align="char">23.26</td></tr><tr><td>8</td><td>48/M</td><td>TAC/GCs</td><td align="char">50.55</td><td align="char">36.30</td><td align="char">0.45</td><td align="char">135.90</td></tr><tr><td>9</td><td>45/F</td><td>TAC/GCs</td><td align="char">21.41</td><td align="char">15.04</td><td align="char">2.04</td><td align="char">32.52</td></tr><tr><td>10</td><td>53/M</td><td>cCTX/GCs</td><td align="char">1016.78</td><td align="char">4.51</td><td align="char">5.18</td><td>0.01 (negative)</td></tr><tr><td>11</td><td>24/M</td><td>cCTX/GCs</td><td align="char">525.25</td><td align="char">10.79</td><td align="char">9.21</td><td align="char">46.58</td></tr><tr><td>12</td><td>45/M</td><td>TAC/GCs</td><td align="char">221.81</td><td align="char">1.36</td><td align="char">0.45</td><td align="char">82.92</td></tr></tbody></table><table-wrap-foot><fn id="tspara0050"><p>aPLA2R &#x0003e; 20 RU/ml were considered positive.</p></fn><fn id="tspara0055"><p>aPLA2R, Antibodies to m-type phospholipase A2 receptor; cCTX, cyclical cyclophosphamide; F, female; GCs, glucocorticoids; M, male; NA, not available; RU, resonance unit; TAC, tacrolimus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table&#x000a0;4</label><caption><p>Outcomes of subjects treated with secondary immunosuppression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><italic>Age/</italic>sex</th><th rowspan="2">Indication</th><th colspan="2">Prior to 1st (TAC/GCs)<hr/></th><th colspan="2">Prior to cCTX/GCs<hr/></th><th colspan="2">2 mo<hr/></th><th colspan="2">4 mo<hr/></th><th colspan="2">6 mo<hr/></th><th colspan="3">aPLA2R (RU/ml)<hr/></th></tr><tr><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/d)</th><th>1</th><th>2</th><th>3</th></tr></thead><tbody><tr><td>24/M</td><td>Resistant</td><td align="char">2.30</td><td align="char">1.62</td><td align="char">4.70</td><td align="char">2.90</td><td align="char">2.50</td><td align="char">2.32</td><td align="char">1.20</td><td align="char">3.59</td><td align="char">0.6</td><td align="char">4.32</td><td align="char">0.45<xref rid="tbl4fna" ref-type="table-fn">a</xref></td><td align="char">27.27</td><td align="char">0.10</td></tr><tr><td>45/M</td><td>Resistant</td><td align="char">10.30</td><td align="char">1.42</td><td align="char">3.00</td><td align="char">2.16</td><td align="char">2.40</td><td align="char">1.80</td><td align="char">2.70</td><td align="char">2.07</td><td align="char">3.00</td><td align="char">2.19</td><td align="char">938.21</td><td align="char">201.95</td><td align="char">182.39</td></tr><tr><td>26/M</td><td>Resistant</td><td align="char">6.60</td><td align="char">1.80</td><td align="char">7.50</td><td align="char">2.47</td><td align="char">1.30</td><td align="char">3.05</td><td align="char">0.76</td><td align="char">4.10</td><td align="char">0.71</td><td align="char">3.68</td><td align="char">217.09</td><td align="char">186.67</td><td align="char">52.23</td></tr><tr><td>41/F</td><td>Relapse</td><td align="char">5.00</td><td align="char">2.20</td><td align="char">4.20</td><td align="char">2.91</td><td align="char">3.76</td><td align="char">2.64</td><td align="char">0.86</td><td align="char">3.65</td><td align="char">0.88</td><td align="char">4.01</td><td align="char">203.46</td><td align="char">364.23</td><td align="char">0.81</td></tr><tr><td>18/F</td><td>Resistant</td><td align="char">5.70</td><td align="char">1.50</td><td align="char">3.90</td><td align="char">2.59</td><td align="char">4.50</td><td align="char">1.10</td><td align="char">1.50</td><td align="char">2.16</td><td align="char">2.50</td><td align="char">2.48</td><td align="char">1468.54</td><td align="char">440.92</td><td align="char">359.30</td></tr><tr><td>22/M</td><td>Relapse</td><td align="char">7.38</td><td align="char">1.90</td><td align="char">11.50</td><td align="char">2.62</td><td align="char">2.40</td><td align="char">3.21</td><td align="char">1.40</td><td align="char">3.57</td><td align="char">0.80</td><td align="char">4.10</td><td align="char">118.80</td><td align="char">235.18</td><td align="char">0.37</td></tr><tr><td>55/M</td><td>Resistant</td><td align="char">6.23</td><td align="char">4.40</td><td align="char">14.70</td><td align="char">3.19</td><td align="char">3.20</td><td align="char">3.70</td><td align="char">2.01</td><td align="char">3.80</td><td align="char">0.28</td><td align="char">3.96</td><td align="char">0.45<xref rid="tbl4fna" ref-type="table-fn">a</xref></td><td align="char">156.51</td><td align="char">0.29</td></tr><tr><td>45/F</td><td>Relapse</td><td align="char">7.40</td><td align="char">2.40</td><td align="char">5.00</td><td align="char">2.83</td><td align="char">1.00</td><td align="char">3.42</td><td align="char">0.15</td><td align="char">4.50</td><td align="char">0.20</td><td align="char">4.13</td><td align="char">21.41</td><td align="char">32.52</td><td align="char">0.31</td></tr><tr><td>48/M</td><td>Relapse</td><td align="char">6.00</td><td align="char">1.85</td><td align="char">4.00</td><td align="char">2.77</td><td align="char">1.50</td><td align="char">2.20</td><td align="char">1.00</td><td align="char">3.90</td><td align="char">0.96</td><td align="char">3.90</td><td align="char">50.55</td><td align="char">135.90</td><td align="char">0.59</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><italic>Age/</italic>sex</th><th rowspan="2">Indication</th><th colspan="2">Prior to 1st (CTX/GCs)<hr/></th><th colspan="2">Prior to TAC<hr/></th><th colspan="2">6 mo<hr/></th><th colspan="2">12 mo<hr/></th><th colspan="2">18 mo<hr/></th><th colspan="3">aPLA2R (RU/ml)<hr/></th></tr><tr><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>1</th><th>2</th><th>3</th></tr></thead><tbody><tr><td>40/M</td><td>Resistant</td><td align="char">7.50</td><td align="char">1.58</td><td align="char">4.60</td><td align="char">3.80</td><td align="char">1.90</td><td align="char">4.00</td><td align="char">2.80</td><td align="char">3.72</td><td align="char">7.92</td><td align="char">2.85</td><td align="char">350.87</td><td align="char">71.83</td><td align="char">142.34</td></tr><tr><td>58/F</td><td>Resistant</td><td align="char">4.40</td><td align="char">2.95</td><td align="char">3.80</td><td align="char">2.70</td><td align="char">2.50</td><td align="char">3.42</td><td align="char">4.86</td><td align="char">3.10</td><td align="char">5.18</td><td align="char">3.35</td><td align="char">393.01</td><td align="char">76.72</td><td align="char">55.19</td></tr><tr><td>54/M</td><td>Resistant</td><td align="char">4.00</td><td align="char">2.20</td><td align="char">4.63</td><td align="char">2.60</td><td align="char">4.30</td><td align="char">2.90</td><td align="char">4.60</td><td align="char">2.20</td><td>Expired</td><td>Expired</td><td align="char">0.45</td><td align="char">0.45</td><td>NA</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><italic>Age/</italic>sex</th><th rowspan="2">Indication</th><th colspan="2">Prior to primary IST<hr/></th><th colspan="2">Prior to rituximab<hr/></th><th colspan="2">2 mo<hr/></th><th colspan="2">4 mo<hr/></th><th colspan="2">6 mo<hr/></th><th colspan="3">aPLA2R (RU/ml)<hr/></th></tr><tr><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>Proteinuria (g/d)</th><th>Serum albumin (g/dl)</th><th>1</th><th>2</th><th>3</th></tr></thead><tbody><tr><td>45/M<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td>Resistant</td><td align="char">6.50</td><td align="char">2.42</td><td align="char">3.46</td><td align="char">2.59</td><td align="char">1.2</td><td align="char">2.48</td><td align="char">4.5</td><td align="char">3.13</td><td align="char">4.31</td><td align="char">3.15</td><td align="char">326.73</td><td align="char">578.30</td><td align="char">138.87</td></tr><tr><td>48/F<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td>Relapse</td><td align="char">4.40</td><td align="char">2.50</td><td align="char">3.50</td><td align="char">2.60</td><td align="char">3.23</td><td align="char">3.46</td><td align="char">0.92</td><td align="char">3.48</td><td align="char">0.53</td><td align="char">3.60</td><td align="char">337.16</td><td align="char">221.71</td><td align="char">0.85</td></tr><tr><td>18/M<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td>Resistant</td><td align="char">6.29</td><td align="char">1.90</td><td align="char">4.00</td><td align="char">1.90</td><td align="char">1.80</td><td align="char">2.12</td><td align="char">2.00</td><td align="char">2.02</td><td align="char">3.67</td><td align="char">2.72</td><td align="char">841.25</td><td align="char">144.89</td><td align="char">16.18</td></tr><tr><td>34/M<xref rid="tbl4fnc" ref-type="table-fn">c</xref></td><td>Resistant</td><td align="char">14.80</td><td align="char">2.40</td><td align="char">4.20</td><td align="char">3.25</td><td align="char">2.40</td><td align="char">3.54</td><td align="char">0.08</td><td align="char">4.04</td><td align="char">1.62</td><td align="char">4.07</td><td align="char">61.32</td><td align="char">101.85</td><td align="char">3.14</td></tr><tr><td>60/F<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td>Relapse</td><td align="char">3.10</td><td align="char">2.40</td><td align="char">5.16</td><td align="char">3.30</td><td align="char">2.44</td><td align="char">3.50</td><td align="char">1.08</td><td align="char">3.70</td><td align="char">1.83</td><td align="char">3.80</td><td align="char">214.13</td><td align="char">322.37</td><td align="char">7.70</td></tr></tbody></table><table-wrap-foot><fn id="tspara0065"><p>Time frames are as follows: 1&#x02014;before starting primary immunosuppression, 2&#x02014;before starting second line agent, 3&#x02014;at completion of second line agent (6 months for patients who received CTX/GCs or rituximab as second line agent and 12 months for those who received tacrolimus as second line agent).</p></fn><fn id="tspara0070"><p>aPLA2R, antibodies to m-type phospholipase A2 receptor; cCTX, cyclical cyclophosphamide; F, female; GCs, glucocorticoids; IST, immunosuppressive therapy; M, male; NA, not available; RU, resonance unit; TAC, tacrolimus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0045">Cases with baseline aPLA2R negative, but serial aPLA2R positive (also had enhanced staining for PLA2R in glomeruli positive).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnb"><label>b</label><p id="ntpara0050">Primary immunosuppression was TAC/GCs.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnc"><label>c</label><p id="ntpara0055">Primary immunosuppression was cCTX/GCs.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.2"><title>Adverse Events</title><p>The adverse events at the end of 12 months were mentioned elsewhere.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> The eGFR calculated by the Modification of Diet in Renal Disease formula showed a reduction from baseline through 24 months in the TAC/GCs group (<italic>P</italic>&#x000a0;= 0.001), whereas no change was noted in the cCTX/GCs group (<italic>P</italic>&#x000a0;= 0.23) (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>) (intention to treat). The mixed model showed no significant differences in eGFR levels between the 2 study groups at various time points. However, in within group comparisons of eGFR levels over time, the fixed-effect mixed model showed significant reduction (<italic>P</italic>&#x000a0;=&#x000a0;0.003) in eGFR in TAC/GCs group compared with baseline, whereas no significant reductions (<italic>P</italic>&#x000a0;= 0.108) in eGFR were observed for cCTX/GCs group. There were no significant differences between both groups at various time points. Between 12 and 24 months, there were 3 episodes (8.57%) and 2&#x000a0;(5.71%) of upper respiratory tract infections in the TAC/GCs and cCTX/GCs groups, respectively, of which 1 patient (who also received TAC for resistant disease) in the cCTX/GCs group died due to tuberculosis. This patient was off any immunosuppression 6 months prior to his death.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Graphical representation of estimated glomerular filtration rate (eGFR) over various time points. The values are expressed as means and SDs (vertical lines). BL, baseline; cCTX, cyclical cyclophosphamide; GCs, glucocorticoids; TAC, tacrolimus.</p></caption><graphic xlink:href="gr3"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p>This is the first study to show the comparative efficacy of TAC/GCs versus cCTX/GCs, and it shows that 2 years after therapy initiation for nonimmunosuppressive symptomatic treatment refractory PMN, TAC/GCs was inferior to cCTX/GCs.</p><p>Praga <italic>et&#x000a0;al.</italic>,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> enrolled 48 subjects of which 25 received TAC for a period of 18 months and 23 received conservative therapy. At the end of 6, 12, and 18 months of therapy, 56%, 72%, and 76% of the subjects were in clinical remission, respectively. At all the time points, the remission rates in the TAC group was significantly better than in the conservative therapy group. Twenty-six percent of the subjects in the conservative treatment group had 50% increases in serum creatinine compared with 4% on TAC (<italic>P</italic>&#x000a0;= 0.03). The benefits of TAC therapy were marred by the 50% relapse rate on stopping the drug.</p><p>There are at least 3 randomized controlled trials from China that have compared TAC/GCs with CTX/GCs for management of PMN,<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref> but they failed to find a difference in remission rates. However, none of the studies have reported their outcomes after stopping TAC. Praga<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> advocated long-term treatment with the lowest effective doses to avoid the relapse of nephrotic syndrome. However, the data from transplant literature suggest that over three-fourths of the subjects on CNI therapy developed biopsy-proven nephrotoxicity in 1 year, and this number was over 90% by 5 years.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> In a small observational study of TAC in steroid-dependent minimal change disease, we observed that 36% of the subjects had relapse of nephrotic syndrome and needed continuation of TAC for maintenance of remission. All 4 subjects underwent screening biopsy at 96 months, of which, 75% had, evidence of chronic nephrotoxicity.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Compared with patients on cCTX/GCs, those on TAC/GCs had significant reduction in eGFR at various time points compared with baseline. This may be partly explained by nephrotoxic potential of TAC.<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref></p><p>The relapse rate was also higher in the TAC group than in subjects on cCTX/GCs. On critical analysis, it is apparent that higher relapse rate with TAC therapy affected the final outcome. Although, the study was designed as a noninferiority study based on percentage remission at 12 months rather than at 24 months, extended follow-up suggests that CTX/GCs patients have better rates of remission maintenance than do those on TAC/GCs.</p><p>These results support and extend the findings of Cattran <italic>et&#x000a0;al.</italic><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> that suggest that CNI-induced remission is usually temporary. In contrast, 2 randomized controlled trials have documented the long-term efficacy of cCTX/GCs in the management of PMN. Ponticelli <italic>et&#x000a0;al.</italic><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and Jha <italic>et&#x000a0;al.</italic><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> reported an initial remission rate of 82% and 72%, respectively, with a relapse rate of about 25%. The 10-year renal survival in the cyclical alkylating agents/GCs and placebo was 89% to 92% and 60% to 65%, respectively.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib15" ref-type="bibr">15</xref> Use of CTX therapy has been clouded by 2 side effects&#x02014;gonadal dysfunction and risk of malignancy. Most of the patients receiving cCTX/GCs receive a cumulative CTX dose in excess of 150 mg/kg, which can compromise gonadal function and would be one of the limiting factors for use of the drug.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Van den Brand <italic>et&#x000a0;al.</italic><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> reported a 3-fold increase in the risk of malignancy in CTX-treated PMN subjects. Most of their patients received oral CTX (1.5 mg/kg) therapy for 12 months.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> None of the subjects on cCTX/GCs therapy in the study by Jha <italic>et&#x000a0;al.</italic><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> and Ponticelli <italic>et&#x000a0;al.</italic><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> developed any malignancy after 10 years of follow-up.</p><p>With respect to the treatment of patients with refractory or dependent PMN, cCTX/GCs were able to induce a response in 77% of TAC/GCs resistant or dependent cases, whereas TAC alone therapy was effective in only one-third of cCTX/GCs resistant subjects. Rituximab was effective in 60% of TAC/GCs or cCTX/GCs resistant or dependent PMN cases. However, most of the responses reported are with short-term follow-up. The report clearly suggests that cCTX/GCs could be potentially used in CNI-resistant PMN.</p><p>The study is limited by a lack of follow-up of significant duration to gauge long-term complications. To conclude, at 24 months after therapy initiation for nonimmunosuppressive symptomatic treatment refractory PMN, cCTX/GCs are better than TAC/GCs.</p></sec><sec id="sec4"><title>Disclosure</title><p>All the authors declared no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><article-title>Chapter 7: Idiopathic membranous nephropathy</article-title><source>Kidney Int Suppl</source><volume>2</volume><year>2012</year><fpage>186</fpage><lpage>197</lpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>van den Brand</surname><given-names>J.A.</given-names></name><name><surname>van Dijk</surname><given-names>P.R.</given-names></name><name><surname>Hofstra</surname><given-names>J.M.</given-names></name><name><surname>Wetzels</surname><given-names>J.F.</given-names></name></person-group><article-title>Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy</article-title><source>Clin J Am Soc Nephrol</source><volume>9</volume><year>2014</year><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">24855280</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>R.</given-names></name><name><surname>Hn</surname><given-names>H.K.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name></person-group><article-title>Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial</article-title><source>Nephrology (Carlton)</source><volume>21</volume><year>2016</year><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">26205759</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids</article-title><source>J&#x000a0;Nephrol</source><volume>26</volume><year>2013</year><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">22956434</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.Y.</given-names></name></person-group><article-title>Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial</article-title><source>Am J Med Sci</source><volume>339</volume><year>2010</year><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">20220333</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial</article-title><source>Contrib Nephrol</source><volume>181</volume><year>2013</year><fpage>152</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">23689577</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Cattran</surname><given-names>D.C.</given-names></name><name><surname>Appel</surname><given-names>G.B.</given-names></name><name><surname>Hebert</surname><given-names>L.A.</given-names></name></person-group><article-title>Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial</article-title><source>Kidney Int</source><volume>59</volume><year>2001</year><fpage>1484</fpage><lpage>1490</lpage><pub-id pub-id-type="pmid">11260412</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>du Buf-Vereijken</surname><given-names>P.W.</given-names></name><name><surname>Branten</surname><given-names>A.J.</given-names></name><name><surname>Wetzels</surname><given-names>J.F.</given-names></name><collab>Membranous Nephropathy Study Group</collab></person-group><article-title>Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate</article-title><source>Nephrol Dial Transplant</source><volume>19</volume><year>2004</year><fpage>1142</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">14993502</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ponticelli</surname><given-names>C.</given-names></name><name><surname>Altieri</surname><given-names>P.</given-names></name><name><surname>Scolari</surname><given-names>F.</given-names></name></person-group><article-title>A&#x000a0;randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy</article-title><source>J&#x000a0;Am Soc Nephrol</source><volume>9</volume><year>1998</year><fpage>444</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">9513907</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Praga</surname><given-names>M.</given-names></name><name><surname>Barrio</surname><given-names>V.</given-names></name><name><surname>Juarez</surname><given-names>G.F.</given-names></name></person-group><article-title>Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial</article-title><source>Kidney Int</source><volume>71</volume><year>2007</year><fpage>924</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">17377504</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>V.</given-names></name><name><surname>Ganguli</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>T.K.</given-names></name></person-group><article-title>A&#x000a0;randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy</article-title><source>J&#x000a0;Am Soc Nephrol</source><volume>18</volume><year>2007</year><fpage>1899</fpage><lpage>1904</lpage><pub-id pub-id-type="pmid">17494881</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Praga</surname><given-names>M.</given-names></name></person-group><article-title>Response to &#x0201c;Tacrolimus in membranous nephropathy&#x0201d;</article-title><source>Kidney Int</source><volume>74</volume><year>2008</year><fpage>824</fpage><pub-id pub-id-type="pmid">18756298</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Nankivell</surname><given-names>B.J.</given-names></name><name><surname>Borrows</surname><given-names>R.J.</given-names></name><name><surname>Fung</surname><given-names>C.L.</given-names></name></person-group><article-title>The natural history of chronic allograft nephropathy</article-title><source>N&#x000a0;Engl J Med</source><volume>349</volume><year>2003</year><fpage>2326</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">14668458</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>D.A.</given-names></name><name><surname>Nada</surname><given-names>R.</given-names></name></person-group><article-title>Chronic nephrotoxicity limits successful use of Tacrolimus in the management of adult steroid-dependent minimal change disease</article-title><source>Nephrology (Carlton)</source><volume>20</volume><year>2015</year><fpage>384</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">25872662</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Ponticelli</surname><given-names>C.</given-names></name><name><surname>Zucchelli</surname><given-names>P.</given-names></name><name><surname>Passerini</surname><given-names>P.</given-names></name></person-group><article-title>A&#x000a0;10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy</article-title><source>Kidney Int</source><volume>48</volume><year>1995</year><fpage>1600</fpage><lpage>1604</lpage><pub-id pub-id-type="pmid">8544420</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Jarrell</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>E.V.</given-names></name><name><surname>Barr</surname><given-names>R.</given-names></name></person-group><article-title>Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat</article-title><source>Cancer Res</source><volume>47</volume><year>1987</year><fpage>2340</fpage><lpage>2343</lpage><pub-id pub-id-type="pmid">3105875</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>This study was supported by a research grant to RR from the Indian Society of Nephrology. The report was presented as oral presentation at ERA-EDTA 2016, Vienna.</p></ack></back></article>